cyrilzakka/clinical-trials huggingface dataset:
The Use of Oral Steroids in the Treatment of Cellulitis

The prevalence of cellulitis in society is very high, as much as 3% of visits to Emergency Departments are for the treatment of this disease. The treatment of cellulitis varies depending on the severity. Low severity cases are treated with pain control and antibiotics by mouth and high severity are treated with antibiotics intravenously and pain control. The investigator's hypothesis is to see if the addition of steroids, which are known to decrease inflammation, will decrease the length of the disease process. If so, it will decrease the length of stay if IV antibiotics are needed, it will decrease duration of days out of work and decrease the overall pain control required and therefore patient satisfaction.

The incidence of cellulitis is about 24.6 cases per 1000 person-years, which is an estimate, since cellulitis is not a reportable disease. In some Emergency Departments up to 3% of visits are for cellulitis. Depending on the severity of the disease, some are treated as outpatients, and others are admitted for IV antibiotics. In some Emergency Departments cases of cellulitis are treated in an observation area for 23 hours with doses of IV antibiotics. My proposed research is to see if the addition of one dose of prednisone the treatment will decrease the inflammatory reaction enough to decrease length of stay and treatment and increase patient satisfaction.

Eligibility Criteria:
Inclusion Criteria:

* 18-70 years old
* signs/symptoms of cellulitis

Exclusion Criteria:

* steroid use in last 2 weeks
* hx of adrenal insufficiency
* suspicion for dvt or abcess
* systemic signs of sepsis
* ICU admission
Proper Dosage of Ketamine in Intravenous Regional Anesthesia

Ketamine added to Lidocaine can increase duration of pain relief following intraveonous regional anesthesia (IVRA). The purpose of this dose response study is to determine the minimum effective dosage of intravenous Ketamine, added to 3 mg/kg of Lidocaine. We anticipate that one dosage will provide us with the proper balance between sufficient anesthesia and minimal side effects.


Eligibility Criteria:
Inclusion Criteria:

1. Age: 18-70
2. Weight: 50-100 kg
3. ASA: I, II, III
4. Carpal tunnel syndrome surgery, tenolysis, ganglion removal or any peripheral hand surgery that can be done by IVRA.

Exclusion Criteria:

1. Contraindication to IVRA such as sickle cell disease.
2. Any known hypersensitivity reaction to Ketamine.
3. History of chronic pain or regular medication with analgesics.
4. History of opioid dependence.
5. Drug of alcohol abuse.
6. Psychiatric disorder.
7. Allergy to acetaminophen or codeine
Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners

Objectives:

Our specific aims are to:

Aim 1: Examine the feasibility of a couple-based meditation program in 50 patients with metastatic lung cancer and their partners.

Aim 2: Establish the initial efficacy of a couple-based meditation program in patients and their partners regarding physical, psychological, and spiritual quality of life outcomes.


Eligibility Criteria:
Inclusion Criteria:

1. ALL PHASES, PATIENTS ONLY: Diagnosed with stage IV Non-Small Cell Lung Cancer (NSCLC)
2. ALL PHASES, PATIENTS ONLY: Currently receiving treatment (e.g. radiotherapy, chemotherapy) at MD Anderson Cancer Center
3. ALL PHASES, PATIENTS ONLY: Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2
4. ALL PHASES, PATIENTS ONLY: Have a romantic partner with whom they have resided for a minimum of 6 months
5. ALL PHASES, PATIENTS AND PARTNERS: Must be at least 18 years old
6. ALL PHASES, PATIENTS AND PARTNERS: Able to read and speak English
7. ALL PHASES, PATIENTS AND PARTNERS: Able to provide consent.

Exclusion Criteria:

1. ALL PHASES, PATIENTS AND PARTNERS: Not oriented to time, place, or person as deemed by the clinical team
2. ALL PHASES, PATIENTS AND PARTNERS: Regular (self-defined) participation in psychotherapy or a formal cancer support group
3. ALL PHASES, PATIENTS AND PARTNERS: Prior enrollment in a couple-based mind-body intervention research study (protocols 2011-1179, 2013-0496, 2014-0036) conducted by the principal investigator including phase 1 or phase 2 of the current study.
Novel Device to Assess Endotracheal Tube Migration

To evaluate the ability of the SonarMed AirWave to provide clinicians with information that enables them to confirm continuous proper placement of the endotracheal tube. This initial study is prospective, observational, looking at CXR results, and comparing those to AirWave system output data.


Eligibility Criteria:
Inclusion Criteria

Subjects will be eligible for inclusion in the study if they meet ALL of the following criteria:

* Oral or nasal endotracheal intubation, anticipated to last at least 48 hours
* Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm
* Subject must be at least 18 years old (no upper age limitation)
* English speaking patients/decision makers.

Exclusion Criteria

* Subjects ventilated through a tracheostomy
* Subjects under 18 years of age
A New Classification and Interventional Therapy for Coronary Artery Ectasia

This study is aim to present a new classification for coronary artery ectasia and find the best interventional therapy for different types of patients were treated and studied.

Coronary artery ectasia refers to a variety of reasons cause coronary artery expansion, its diameter is more than 1.5 times that of the adjacent normal coronary artery. Clinical symptoms include angina, myocardial infarction and sudden death.At present, there is no consensus on the mechanism and treatment of the disease, which may be related to the structural failure of the vessel wall and abnormal hemodynamics in the dilated segment.Most of the existing studies are case reports or single-center retrospective analysis of small samples, with low level of evidence.As a common fluid analysis method in the field of engineering, computational fluid dynamics can effectively simulate the movement and stress state of blood under reasonable model assumptions.By comparing the preoperative and postoperative data of real cases, the validity of simulation analysis results can be tested.The purpose of this study is to carry out a multi-center study combining morphological and hemodynamic factors, to propose a new classification and interventional treatment strategy for atherosclerotic coronary artery ectasia, and to provide evidence-based medical evidence for the development of treatment guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Male or non-pregnant female aged ≥18 years;
* Coronary artery ectasia was confirmed by coronary CT or coronary angiography;
* The patient (or guardian) is fully aware of the study process and signs the informed consent;
* Patients were able to undergo subsequent follow-up.

Exclusion Criteria:

* Congenital coronary artery fistula;
* kawasaki disease;
* Treponema pallidum or lyme treponema;
* Marfan;
* Primary lymphoma;
* Coronary artery pseudoaneurysm;
* Acute infectious disease or autoimmune disease;
* Hematological Disease;
* Severe liver and kidney dysfunction (AMI one week later, alanine transaminase ≥3 times the upper limit of normal value; Creatinine clearance rate ≤30ml/min or blood creatinine ≥2.5mg/dl);
* Unstable craniocerebral disease;
* Cancer;
* Severe cognitive impairment (dementia or severe mental illness);
* Patients with severe physical disabilities who cannot be followed up regularly;
* Other serious uncontrolled systemic diseases;
* Female patient who is ready to become pregnant, already pregnant or nursing;
* Contraindications to percutaneous coronary intervention (PCI) : for patients at high risk of massive bleeding in the digestive tract, intracranial and other areas, or allergic to contrast agents;
* Cannot tolerate dual antiplatelet therapy for at least 1 year;
* Age \< 18 years old;
* Patients who are unable or unwilling to sign informed consent
Exercise and Branched Chain Amino Acids (BCAA)Requirements in Older Men

Likely, branched chain amino acid (BCAA) requirements are increased in older strength-trained (ST) individuals. If so, supplementation in this group will maximize muscle protein synthesis (MPS) and minimize loss of muscle with age (sarcopenia).

We hypothesize that the dietary requirement for the branched chain amino acids (BCAA) in an older strength-trained (ST) population will be greater than the current recommendation (RDA). If so, a greater intake of BCAA together with ST is necessary if one aims to maximize muscle protein synthesis (MPS). Currently, the BCAA requirement in the ST older population (55-65 y) is unknown. This is critical information especially given the value of ST for overall health.

Eligibility Criteria:
Inclusion Criteria:

* Recreationally active (\~2-3 h/wk of physical activity) healthy older men (55-65 y)
* A minimum of 4 month weight training experience

Exclusion Criteria:

* Have symptoms or take medication for respiratory disease
* Have symptoms or take medication for cardiovascular disease
* Have symptoms or take medication for metabolic disease
* Have symptoms or take mediation for neuromuscular disease
* Use heart rate or blood pressure medications
* Use any medications with side effects of dizziness, lack of motor control, or slowed reaction time
* Have an excessive alcohol intake (more than 2 drinks per day)
* Have any cardiovascular or neuromuscular limitations to exercise
* Are allergic to milk or milk products
* Use anabolic steroids or performance enhancing drugs
Prophylactic Mesh Implantation for the Prevention of Incisional Hernia

Incisional hernias are primarily repaired using prosthetic meshes. In Switzerland such meshes are mainly implanted via open or laparoscopic approach. The differential impact of these two types of surgical technique on recurrence rate will be investigated with this study.

With this multicenter cohort study the outcomes of laparoscopic and open incisional hernia repair will be investigated prospectively. Hernia recurrence is the main outcome measure.

Background

Incisional hernia is one of the most common complication in general abdominal surgery. An overall incidence of 20% has been found in retrospective studies, ranging in up to 50% of patients with selected risk factors such as obesity.

In the general surgical patient the current standard is the closure of the abdominal wall using a running, slowly absorbable suture. With this well established clinical practice the incidence remains high and incisional hernia repair must be performed frequently in order to treat patients'symptoms and to prevent progression of the hernia an possible complications.

Consequently, in high risk patients prophylactic mesh implantation is performed routinely in our institution.

Objective

* Occurrence of at least two of the following factors:

  * Male gender
  * Malignant tumor present
  * Body mass index above 25kg/m2
  * Previous laparotomy
* Elective operation
* Patient \>18 years
* Written informed consent

Methods

Prospective,two armed, controlled, randomized study

Eligibility Criteria:
Inclusion Criteria:

* Occurrence of at least two of the following factors:

  * Male gender
  * Malignant tumor present
  * Body mass index above 25
  * Previous laparatomy
* Elective operation
* Patient \> 18 years
* Written informed consent

Exclusion Criteria

* Previous intra-abdominal mesh placement
* Emergency procedures
* Previous incisional hernia
* Inflammatory bowel disease
Carpal Tunnel Release Via Two Small Incisions Comparing With Via Standard Incision And Under Endoscope

Carpal Tunnel Release via Two Small Incisions Comparing With via Standard Incision And Under Endoscope.

Carpal tunnel syndrome (CTS) affects over 60 million people worldwide. If a regimen of conservative management has failed, surgical release of the median nerve is warranted. Numerous approaches for carpal tunnel release have been described that range from an open technique to a limited incision to endoscopic release. In addition, partial excision of the flexor retinaculum is advocated by some surgeons because of obtaining better outcomes. However, the procedure is difficult to be accomplished through small incisions owing to poor visualization. Currently, balance of incision, visualization, and partial excision of the flexor retinaculum is still controversial.

The objective of this report is to introduce carpal tunnel release with partial excision of the flexor retinaculum through two small incisions. The procedures were performed under lighted head magnifier. This is the first report on the use of our technique. For comparison, the investigators also included two other groups of standard open carpal tunnel release with partial excision of the flexor retinaculum and endoscopic carpal tunnel release without excision of the flexor retinaculum.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of CTR was established based on Evidence for Surgical Treatment issued by the British Society for Surgery of the Hand (2003)
* Patients with moderate, severe, and very severe symptom.

Exclusion Criteria:

* Mild symptom.
* Finding had a ganglion based on preoperative ultrasound.
* Associated with infection, gout, or diabetes.
* Patients who discontinued intervention and lost to follow-up.
Efficacy of Postoperative Pain Control Between Transarticular VS Periartiucular Multimodal Drug Infiltration in Total Hip Arthroplasty: Double-blinded Randomized Control Trial

This research aim to improve postoperative outcome in total hip arthroplasty(THA) by using local mixture infiltration as bupivacaine + NSAID + epinephrine + tranxemic acid. In the present time these mixture components has shown to improve THA outcome by aspect of postoperative pain control, postoperative opioid consumption, postoperative bleeding, LOS and postoperative rehabilitation without increasing complication but the accuracy of infiltration technique which gives the best outcome has not been yet discovered.Recently study by Hashimoto et al has risen that these technique can be administrated by both periarticular and intra-articular approach.By considering the complexity of human anatomy around the hip tissue we assume that the intra-articular(transarticular) may given equivalence (may be better) outcome with lowering procedural related complication comparing to periarticular infiltration approach.


Eligibility Criteria:
Inclusion Criteria:

* patient who would go on cemented and cementless THA
* age 45-60 years of age
* voluntary decision exclusion criteria
* bilateral THA
* revision surgery
* history of pelvic and hip surgery previously
* allergy to medication in protocol
* CKD stage 4-5, chronic liver disease with Child Pugh B or C
* pregnancy
* history of hip injection
* U/D
* hypercoagulable state
* abnormal laboratory coagulation study as INR \> 1.4 or aPTT \> 1.4
* abnormal platelet function
* thrombocytopenia
* PE , DVT, ischemic stroke, CAD/ischemic heart disease
* use of anticoagulant or hormonal usage
* anesthesia by general anesthesia or additional nerve block
* can not understand PCA usage
* use postopertive wound drainage
Detailed Pain Pattern After Laparoscopic Inguinal Hernia Repair

Pain after laparoscopic groin hernia repair consist of different pain components (overall pain, shoulder pain, incisional pain and visceral pain). Thus it is important to find out which of these pain components that is most severe, so intervention can be targeted.

Details about the components of early pain after laparoscopic groin hernia repair are lacking. A description of each component (overall pain, shoulder pain,incisional pain and visceral pain) is needed, so intervention against the different pain components can be targeted.

Patients fill out questionnaires about pain before operation and day 0-3 after operation.

Eligibility Criteria:
Inclusion Criteria:

* men
* 18-69 years
* uni- or bilateral hernia
* ASA I-II
* Danish speaking

Exclusion Criteria:

* bad compliance
* acute operation
* daily intake of opioids
Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial

Approximately 5% of the world's adult population has some alcohol-related disorder, which in addition is associated with 3% of all deaths in the world. In Brazil, harmful use and dependence on alcohol reach about 10% of the population, with alcohol being one of the main factors of disease and mortality. Although the medications currently used have some efficacy, the adverse effects and relatively long time of treatment are factors that may reduce patients' motivation to continue taking the medication correctly. Therefore, it is necessary to conduct research with new drugs for the treatment of alcoholism. Ibogaine is an alkaloid present in the bush Tabernanthe iboga (iboga), a plant from Central Africa traditionally used in countries such as Gabon and Cameroon. Animal studies and case series suggest that one or a few doses of ibogaine significantly reduce withdrawal symptoms and the intensity of use of various drugs, including opioids, psychostimulants, and alcohol. However, there are no controlled clinical studies that have explored these effects. The aim of the present study is to evaluate the safety, tolerability and efficacy of increasing doses of ibogaine in 12 alcoholic patients. Each patient will be hospitalized for 20 days and receive 3 increasing doses of ibogaine. The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly. The volunteers will also be evaluated 7, 14 and 21 days and 1, 3, 6 and 12 months after leaving the hospital to monitor the consumption of alcohol and other drugs.


Eligibility Criteria:
Inclusion Criteria:

* Literate people
* Diagnosis of alcoholism assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (SCID-V)
* History of at least two previous failed treatments for alcoholism (with drug use and / or psychotherapy)
* Signing the Free and Informed Consent Form.

Exclusion Criteria:

* Presence of any psychiatric diagnosis (excluding alcohol / tobacco / nicotine abuse / dependence) assessed by the SCID-V
* Presence of clinical disease (especially cardiovascular and hepatic diseases), based on interview, physical and laboratory examination (hemogram and electrocardiogram, ECG)
* Absence of family or personal history of bipolar disorder and psychotic disorders
* Absence of recent symptoms of hypomania, mania or psychosis
* Non-literate people
* Pregnant or lactating women
* Recent use of illicit drugs (confirmed by examination in urine).
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of LX4211 following once daily oral administration in subjects with type 2 diabetes mellitus (T2DM) and moderate to severe renal impairment.


Eligibility Criteria:
Inclusion Criteria:

* Adults ≥18 to ≤80 years of age
* History of T2DM for at least 6 months prior to screening
* Moderate to severe renal impairment and not actively on dialysis
* Willing and able to perform self-monitoring of blood glucose
* Willing and able to provide written informed consent

Exclusion Criteria:

* History of type 1 diabetes mellitus, diabetic ketoacidosis (within the previous 6 months), or diabetes resulting from pancreatic disorder or secondary diabetes (from acromegaly and/or Cushing's disease)
* Subjects who have received a renal allograft
* Subjects expecting to require dialysis or to undergo kidney transplantation within 3 months of study dosing
* Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or planned study Day -1
* Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day -2
* History of clinically significant cardiac arrhythmias within 1 year prior to study Day -2
* Subjects with congestive heart failure
* Subjects with uncontrolled Stage III hypertension
* History of 2 or more emergency room visits, doctors' visits, or hospitalizations due to hypoglycemia within the 6 months prior to planned study Day -2
* History of alcohol or illicit drug abuse within 1 year prior to Screening
* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
* Major surgery within 6 months prior to planned study Day -2
* History of any malignancy within the last 5 years
* Triglycerides \>1000 mg/dL at Screening or planned study Day -1
* History of any serious adverse reaction or hypersensitivity to an SGLT inhibitor
* Use of corticosteroids within 2 weeks prior to study Day 1
* Use of any investigational drug within 30 days prior to study Day 1, or investigational protein or antibodies within 60 days of Day 1
* Positive urine pregnancy test at Screening
* Positive urine screen for illicit drug abuse at Screening
* Prior exposure to LX4211
A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes

A single-center, non-interventional prospective observational study in the NSCLC patients with different driver genes

The trial was designed as a single-center non-interventional prospective observational study to explore clinical treatments of the NSCLC patients with different driver genes, the impact factors of patient survivals, and the relevance of gene types, clinical treatments, and distribution of gene types. The follow-up visits, interactions between the investigators and patients, patient questionnaires/quality of life, and other patient information will be uploaded via mobile APP, and webchat every three months.

Eligibility Criteria:
Inclusion Criteria:

* The patients with lung cancer who were performed with next-generation sequencing (NGS) technology from 2015 to 2017;
* The patients who were at least 18 years;
* The pathologically diagnosed patients with non-small cell lung cancer (NSCLC)

Exclusion Criteria:

-None
Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass

The purpose of this study is to examine the effects of bile acids on GLP-1 secretion after Roux-en-Y gastric bypass.


Eligibility Criteria:
Inclusion Criteria:

* Uncomplicated RYGB performed minimum 3 months prior to the study.
* Fasting plasma glucose \< 7.0mM, HbA1c \< 48mmol/mol 3 months after RYGB.

Exclusion Criteria:

* Fasting plasma glucose \> 7.0mM, HbA1c \> 48mmol/mol 3 months after RYGB.
* Dysregulated hypothyroidism, use of antithyroid treatment.
* Late diabetic complications as retinopathy, renal insufficiency, neuropathy or previous pancreatitis.
* Complications to RYGB: Documented reactive hypoglycaemia, severe dumping (vomiting, diarrhea, severe abdominal pain after food intake).